Tag
Finerenone significantly slows kidney function decline and reduces cardiovascular risk in hypertensive non-diabetic CKD patients, with manageable safety profiles, supporting its therapeutic role beyond diabetes.
Finerenone reduces mortality, cardiovascular, and kidney complications in cardio-kidney-metabolic syndrome patients regardless of cancer history, while patients with cancer experience greater disease burden and adverse events.
A prespecified pooled analysis of 18,991 participants found finerenone was associated with a significant reduction in sudden death across chronic kidney disease, type 2 diabetes, and heart failure populations.
This clinical review synthesizes data from the FINEARTS-HF trial, highlighting finerenone’s efficacy in reducing heart failure events and cardiovascular mortality across diverse patient profiles, including those with frailty, obesity,
Finerenone consistently reduces heart failure events and allows reduction of loop diuretic dosages without impacting new loop diuretic initiation, demonstrating a diuretic-sparing effect in HFmrEF/HFpEF patients.
